ResMed Inc. (NYSE:RMD) reached a new 52-week high during trading on Thursday . The company traded as high as $65.14 and last traded at $64.90, with a volume of 246,807 shares changing hands. The stock had previously closed at $64.43.

A number of equities research analysts have recently commented on the stock. Citigroup Inc. upgraded shares of ResMed from a “neutral” rating to a “buy” rating in a report on Wednesday, April 27th. Piper Jaffray Cos. cut shares of ResMed from an “overweight” rating to a “neutral” rating and cut their price target for the company from $65.00 to $57.00 in a report on Wednesday, April 27th. Needham & Company LLC reiterated a “hold” rating on shares of ResMed in a report on Wednesday, April 27th. Canaccord Genuity reiterated a “hold” rating on shares of ResMed in a report on Wednesday, April 27th. Finally, BMO Capital Markets restated a “hold” rating on shares of ResMed in a report on Wednesday, April 27th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of C$59.69.

The firm has a market cap of $9.13 billion and a price-to-earnings ratio of 26.65. The firm has a 50-day moving average of $60.94 and a 200-day moving average of $58.06.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Tuesday, April 26th. The company reported $0.68 EPS for the quarter, missing the consensus estimate of $0.69 by $0.01. During the same period in the previous year, the business posted $0.65 EPS. The company had revenue of $453.90 million for the quarter, compared to analysts’ expectations of $455.32 million. The firm’s quarterly revenue was up 7.4% compared to the same quarter last year. Analysts predict that ResMed Inc. will post $2.66 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 16th. Investors of record on Thursday, May 19th were paid a dividend of $0.30 per share. The ex-dividend date of this dividend was Tuesday, May 17th. This represents a $1.20 annualized dividend and a dividend yield of 1.86%.

In related news, CEO Michael J. Farrell sold 5,975 shares of the business’s stock in a transaction that occurred on Friday, April 15th. The shares were sold at an average price of C$59.34, for a total transaction of C$354,556.50. Following the completion of the transaction, the chief executive officer now owns 154,723 shares in the company, valued at approximately C$9,181,262.82. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Pendarvis sold 6,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 3rd. The stock was sold at an average price of C$56.02, for a total transaction of C$336,120.00. Following the transaction, the insider now owns 80,287 shares of the company’s stock, valued at approximately C$4,497,677.74. The disclosure for this sale can be found here.

A number of hedge funds recently added to or reduced their stakes in RMD. Gulf International Bank UK Ltd increased its stake in ResMed by 1.0% in the fourth quarter. Gulf International Bank UK Ltd now owns 40,849 shares of the company’s stock valued at $2,193,000 after buying an additional 400 shares in the last quarter. GSA Capital Partners LLP increased its stake in ResMed by 454.4% in the fourth quarter. GSA Capital Partners LLP now owns 55,108 shares of the company’s stock valued at $2,959,000 after buying an additional 45,168 shares in the last quarter. Liberty Mutual Group Asset Management Inc. increased its stake in ResMed by 49.4% in the fourth quarter. Liberty Mutual Group Asset Management Inc. now owns 89,442 shares of the company’s stock valued at $4,802,000 after buying an additional 29,576 shares in the last quarter. Vanguard Group Inc. increased its stake in ResMed by 2.1% in the fourth quarter. Vanguard Group Inc. now owns 10,244,386 shares of the company’s stock valued at $550,022,000 after buying an additional 212,360 shares in the last quarter. Finally, Winton Capital Group Ltd increased its stake in ResMed by 13.7% in the fourth quarter. Winton Capital Group Ltd now owns 437,623 shares of the company’s stock valued at $23,496,000 after buying an additional 52,824 shares in the last quarter.

ResMed Inc is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.